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Insulin Independence for 58 Months Following Pancreatic Islet Cell 
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Abdominal Exenteration 
H.l.R. Rile, P.B. Carroll, A. Tzakis, R. Jaffe, C. Ricerdi, T.E. Starzl and A.S. Rae 
THE most successful outcome of pancreatic islet allo-transplantation has been in patients with upper ab-
dominal malignancies who have undergone cluster resec-
tion followed by liver replacement. I.2 Between January 
1990 and June 1992. 11 patients underwent this procedure; 
six (55%) of whom were insulin-independent until demise, 
due to recurrence of the primary disease. We report herein. 
a 58-month postoperative metabolic course of the longest 
survivor of islet allotransplantation. who underwent upper 
abdominal exenteration for hepatocellular carcinoma ne-
cessitating combined liver and islet transplantation. 
MATERIAL AND METHODS 
Patient 
At the time of surgery (1190), the patient was 15 years of age and 
had previously been diagnosed as having fibroJameUar hepatocel-
lular carcinoma that did not respond to repeated transcutaneous 
hepatic intra-arterial administration of chemotherapeutic agents 
(Adriamycin and cis-platinum). She had no metastatic lesions and 
underwent upper abdominal evisceration that included total pan-
createctomy followed by orthotopic )jverallotran.splantation. At 
the culmination of this procedu{'e, 4.7 x 10' islets (5.1 x 10' IEq), 
isolated from the pancreas of the cadaveric liver donor were 
infused into the portal vein. For postoperative immunosuppression, 
only tacrolimus (FK506, Fujisawa Pharmaceutical Co .. Deerfield. 
IL) was used. 
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Isolation of Pancreatic Islets 
Islets were isolated by a modification of the automated method. J 
and further purified by velocity sedimentation on a discontinuous 
Euro-Collins-ficoll density gradient using a cell separator (COBE 
2991'", COBE Laboratories Inc., Lakewood, CO). Islet number. 
purity and viability were determined by dithizone staining. 
Postoperative Assessment of Islet Cell Function 
For precise evaluation of transplanted islets cell function. serial 
determination of levels of plasma glucose, C·peptide and glycosy-
lated hemoglobin (HbA lc) were performed. Additionally. at regu-
lar intervals posttransplantation, attempts were also made to assess 
islets cell responses to stress by oral glucose tolerance test (OGTT), 
Sustacal challenge test and by IV glucose tolerance test (IVGTT). 
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Fig 1. Serial posttransplant 
determinations of C-peptide ac-
tivity following IV glucose toler-
ance test (IVGTT), in a patient 
who underwent liver and islets 
celf allotransplantation subse-
quent to cluster resection ne-
cessitated by upper abdominal 
malignancy. 
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INSULIN INDEPENDENCE FOR 58 MONTHS 
RESULTS AND DISCUSSION 
The clinical and metabolic course during the first 36 months 
following islets cell and liver transplantation have been 
detailed elsewhere? The patient achieved complete inde-
pendence from exogenous insulin at approximately 16 
weeks posttransplantation, and continued to maintain this 
status for up to 58 months, at which time she died due to 
multiple system organ failure precipitated by widespread 
metastases. It must be noted, that at 18 months posttrans-
plantation, the first recurrence of the malignancy was 
observed which manifested itself as a solitary tumor, limited 
to the jaw, necessitating surgical resection followed by a 
course of chemotherapy and local radiation. At that time, 
involvement of the regional lymph nodes was confirmed, 
however, there was no evidence of distant metastases.2 
Similar to our earlier observations,2 IVOTI test performed 
at 57 months posttransplantation revealed a normal C-
peptide response (Fig 1), confirming the preservation of 
~ transplanted islets cell function. Immunohistochemical 
analysis of liver sections obtained at autopsy revealed the 
presence of transplanted islets, which in addition to exhib-
iting normal morphology, stained positively for insulin, 
glucagon, somatostatin, and pancreatic polypeptides. Addi-
tionally. the presence of SlOO+ and UVECT cells suggested 
innervation and organization of vasculature respectively, 
within the islet cell mass. 
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In conclusion, islets obtained from a single donor, when 
infused into a recipient undergoing a "cluster" procedure, 
reversed diabetes and rendered the patient insulin-free for 
up to 58 months posttransplantation. Similar success has 
also been achieved in 5 of 10 additional cluster recipients 
who died insulin-free at various times posttransplantation.2 
On the contrary, long-term insulin-independence has not 
been accomplished in transplant recipients of islets and. 
other whole organ allografts .. ~-Qur ongoing clinicar tnais'~f 
delayed islets cell infusion, which in the rodent model has 
yielded indefinite graft survival,s may however ameliorate 
this discouraging initial outcome witnessed in type I diabet-
ics. 
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